Atenolol for Panic Symptoms
Beta-blockers, including atenolol, are commonly prescribed for symptomatic relief of physical panic symptoms, but the evidence supporting their effectiveness for panic disorder itself is weak and inconsistent. 1
Evidence Assessment
Guideline Perspective on Beta-Blockers for Panic
A 2022 Hypertension guideline explicitly states that "in panic disorder, beta-blockers are commonly prescribed for symptom relief, combined with cognitive behavior therapy and/or a selective serotonin reuptake inhibitors and/or a benzodiazepine." 1 This acknowledges real-world practice but notably positions beta-blockers as adjunctive rather than primary treatment.
Research Evidence: Limited Efficacy
The most recent and highest-quality evidence comes from a 2025 systematic review and meta-analysis that examined beta-blockers across anxiety disorders 2. This study found:
- No evidence for beneficial effect of beta-blockers compared with placebo or benzodiazepines in patients with panic disorder (p ≥ 0.54)
- Small sample sizes and high risk of bias across included studies
- The authors concluded there is a lack of robust evidence of effectiveness despite increasing prescriptions
An earlier 1987 review similarly concluded that "the efficacy of propranolol in patients with panic disorder has not been widely researched, but preliminary results have not been encouraging" and suggested beta-blockers may only provide symptomatic relief for residual somatic complaints like palpitations when combined with other treatments 3.
When Atenolol May Be Appropriate
Target Symptoms
Atenolol may be reasonable for managing specific physical symptoms of panic attacks rather than the panic disorder itself:
- Palpitations
- Tachycardia
- Tremor
- Cardiovascular sensations that trigger or worsen panic
Clinical Context
Consider atenolol when:
- Physical symptoms are prominent and distressing
- Used as adjunctive therapy with evidence-based treatments (SSRIs, cognitive behavioral therapy)
- Patient has failed or cannot tolerate first-line treatments
- Comorbid cardiovascular symptoms require management
Dosing Regimen
Based on FDA labeling and research evidence 4, 5, 6, 7:
Starting dose: 25-50 mg once daily
Typical dose range: 50-100 mg daily
Frequency: Once or twice daily (atenolol has 25-100 mg usual dose range, given twice daily per guidelines) 8, 9, 10
- Start at the lower end (25 mg daily) in elderly or renally-impaired patients
- Titrate based on symptom response and tolerability
- A 2020 preliminary study used atenolol for anxiety symptoms with 86% reporting positive effects 5
- A 1988 study found both propranolol and atenolol effective in generalized anxiety, though atenolol had "unacceptable cardiovascular effects" in some anxious patients 7
Critical Safety Considerations
Absolute Contraindications
- Severe bradycardia (HR <50 bpm)
- Second- or third-degree heart block without pacemaker
- Decompensated heart failure
- Cardiogenic shock
- Severe hypotension (SBP <90 mmHg)
Relative Contraindications
- Asthma or severe COPD: While cardioselective, atenolol can still affect beta-2 receptors at higher doses 8, 10, 8. Recent evidence suggests cardioselective beta-blockers may be safer than previously thought in stable respiratory disease 11, 12, but non-selective agents should be avoided
- First-degree AV block (PR >0.24 seconds) 13
- Peripheral vascular disease
Important Warnings
- Never abruptly discontinue atenolol, especially in patients with coronary disease—taper gradually to avoid rebound effects 8, 9, 10
- Monitor for depression, fatigue, and sexual dysfunction as potential adverse effects 14
- Adjust dose in renal impairment (atenolol is renally excreted): maximum 50 mg daily if CrCl 15-35 mL/min, 25 mg daily if CrCl <15 mL/min 4
Clinical Bottom Line
Atenolol should not be considered a first-line treatment for panic disorder. The evidence base is insufficient to support routine use. However, it may provide symptomatic relief for prominent physical manifestations of panic attacks when used adjunctively with evidence-based treatments like SSRIs and cognitive behavioral therapy. If prescribed, use the lowest effective dose (typically 25-50 mg daily), monitor carefully for adverse effects, and ensure the patient is receiving appropriate primary treatment for the underlying panic disorder.
The 2025 meta-analysis conclusion is sobering: "Beta-blockers are increasingly prescribed for anxiety, yet there is a lack of robust evidence of effectiveness." 2 This disconnect between prescribing patterns and evidence should give clinicians pause before reaching for atenolol as a solution for panic symptoms.